lusutrombopag (Mulpleta)

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

Dosage

  • 3 mg PO QD with or without food for 7 days

Tablets: 3 mg

Adverse effects

Mechanism of action

More general terms

References

  1. 1.0 1.1 1.2 FDA Approved Drugs. July 31, 2018 FDA approves lusutrombopag for thrombocytopenia in adults with chronic liver disease. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm615348.htm
  2. HIGHLIGHTS OF PRESCRIBING INFORMATION MULPLETA<TM> (lusutrombopag tablets) for oral use https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210923s000lbl.pdf

Database